Zhejiang Garden BiopharmaceuticalLtd Future Growth
Future criteria checks 4/6
Zhejiang Garden BiopharmaceuticalLtd is forecast to grow earnings and revenue by 34.7% and 17.2% per annum respectively. EPS is expected to grow by 34.9% per annum. Return on equity is forecast to be 15.1% in 3 years.
Key information
34.7%
Earnings growth rate
34.9%
EPS growth rate
Pharmaceuticals earnings growth | 18.8% |
Revenue growth rate | 17.2% |
Future return on equity | 15.1% |
Analyst coverage | Low |
Last updated | 03 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,854 | 702 | N/A | 654 | 1 |
12/31/2025 | 1,638 | 553 | N/A | 530 | 1 |
12/31/2024 | 1,446 | 418 | N/A | 657 | 1 |
3/31/2024 | 1,108 | 232 | -133 | 131 | N/A |
12/31/2023 | 1,095 | 192 | -85 | 160 | N/A |
9/30/2023 | 1,237 | 179 | -134 | 109 | N/A |
6/30/2023 | 1,274 | 204 | -83 | 190 | N/A |
3/31/2023 | 1,348 | 284 | -45 | 271 | N/A |
1/1/2023 | 1,418 | 384 | -3 | 377 | N/A |
9/30/2022 | 1,427 | 466 | -62 | 449 | N/A |
6/30/2022 | 1,385 | 461 | 24 | 677 | N/A |
3/31/2022 | 1,329 | 543 | -83 | 660 | N/A |
1/1/2022 | 1,117 | 484 | -203 | 512 | N/A |
9/30/2021 | 937 | 409 | -77 | 591 | N/A |
6/30/2021 | 847 | 420 | -223 | 385 | N/A |
3/31/2021 | 699 | 293 | -139 | 455 | N/A |
12/31/2020 | 659 | 263 | -166 | 427 | N/A |
9/30/2020 | 630 | 261 | -341 | 311 | N/A |
6/30/2020 | 645 | 277 | -218 | 366 | N/A |
3/31/2020 | 617 | 276 | -264 | 275 | N/A |
12/31/2019 | 718 | 344 | -80 | 367 | N/A |
9/30/2019 | 763 | 392 | 125 | 410 | N/A |
6/30/2019 | 758 | 384 | 79 | 322 | N/A |
3/31/2019 | 661 | 315 | 91 | 318 | N/A |
1/1/2019 | 660 | 307 | 35 | 253 | N/A |
9/30/2018 | 585 | 252 | 21 | 193 | N/A |
6/30/2018 | 508 | 208 | 92 | 224 | N/A |
3/31/2018 | 569 | 232 | 151 | 229 | N/A |
1/1/2018 | 420 | 130 | N/A | 148 | N/A |
9/30/2017 | 416 | 120 | N/A | 117 | N/A |
6/30/2017 | 403 | 103 | N/A | 98 | N/A |
3/31/2017 | 355 | 60 | N/A | 75 | N/A |
12/31/2016 | 329 | 44 | N/A | 49 | N/A |
9/30/2016 | 272 | 29 | N/A | 65 | N/A |
6/30/2016 | 239 | 17 | N/A | 26 | N/A |
3/31/2016 | 178 | 10 | N/A | 22 | N/A |
12/31/2015 | 151 | 12 | N/A | 43 | N/A |
9/30/2015 | 152 | 22 | N/A | 42 | N/A |
6/30/2015 | 158 | 33 | N/A | 12 | N/A |
3/31/2015 | 163 | 38 | N/A | -16 | N/A |
12/31/2014 | 159 | 37 | N/A | -12 | N/A |
9/30/2014 | 158 | 40 | N/A | 39 | N/A |
12/31/2013 | 184 | 36 | N/A | 114 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300401's forecast earnings growth (34.7% per year) is above the savings rate (2.9%).
Earnings vs Market: 300401's earnings (34.7% per year) are forecast to grow faster than the CN market (21.9% per year).
High Growth Earnings: 300401's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300401's revenue (17.2% per year) is forecast to grow faster than the CN market (13.4% per year).
High Growth Revenue: 300401's revenue (17.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300401's Return on Equity is forecast to be low in 3 years time (15.1%).